Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Senores Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Chlorzoxazone Tablets USP, 250 mg, a therapeutic equivalent version of Paraflex (Chlorzoxazone) is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal condition...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Senores Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mayne Pharma Launches Chlorzoxazone Tablet in the United States
Details : FDA has granted approval of its Abbreviated New Drug Application (ANDA) for chlorzoxazone tablet, 375 mg, 500 mg and 750 mg, in the United States.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Chlorzoxazone
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
